This is a summary of the European public assessment report (EPAR) for M-M-RVaxPro. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use M-M-RVaxPro. For practical information about using M-M-RVaxPro, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication M-M-RVaxPro is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months or older. For use in measles outbreaks, or for post-exposure vaccination, or for use in previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella.
Therapeutic Area (MeSH)
ATC Code
J07BD52
ATC Item
measles, combinations with mumps and rubella, live attenuated
Pharmacotherapeutic Group
Vaccines
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| mumps virus Jeryl Lynn (level B) strain (live, attenuated) | N/A | Mumps virus strain B level jeryl lynn live antigen |
| measles virus Enders’ Edmonston strain (live, attenuated) | N/A | Measles virus vaccine live attenuated |
| rubella virus Wistar RA 27/3 strain (live, attenuated) | N/A | Rubella virus vaccine |
EMA Name
M-M-RVaxPro
Medicine Name
M-M-RVaxPro
Aliases
N/ANo risk management plan link.
